Banco Santander S.A. Raises Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Banco Santander S.A. raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 5.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 126,900 shares of the company’s stock after purchasing an additional 6,900 shares during the period. Banco Santander S.A. owned 0.27% of Pacira BioSciences worth $2,391,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its stake in shares of Pacira BioSciences by 129.4% in the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after buying an additional 2,799,434 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Pacira BioSciences by 269.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after purchasing an additional 288,662 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in Pacira BioSciences in the 3rd quarter worth approximately $793,000. Empowered Funds LLC acquired a new position in shares of Pacira BioSciences during the 3rd quarter worth approximately $3,286,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Pacira BioSciences in the third quarter valued at approximately $493,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on PCRX. HC Wainwright lifted their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Barclays lifted their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Price Performance

Pacira BioSciences stock opened at $23.37 on Friday. The company’s 50 day simple moving average is $23.55 and its 200-day simple moving average is $18.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $31.67. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -11.51 and a beta of 0.86.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.